Endocardial Fibroelastosis: A Comprehensive Review of Pathogenesis, Clinical Manifestations, Diagnostic Modalities, and Management Strategies
Main Article Content
Abstract
Endocardial fibroelastosis (EFE) is a rare and enigmatic myocardial disease characterized by the abnormal accumulation of collagen and elastin fibers in the endocardium, predominantly affecting the left ventricle. This comprehensive review aims to elucidate the pathogenesis, clinical manifestations, diagnostic modalities, and management strategies of EFE. EFE typically presents in infants and young children, although adult cases have been reported. The etiology of EFE remains elusive, with theories implicating genetic, infectious, and autoimmune factors. Clinically, EFE may manifest with symptoms of heart failure, arrhythmias, or sudden cardiac death. Diagnosis often involves echocardiography, cardiac magnetic resonance imaging, and endomyocardial biopsy. Management strategies for EFE are primarily supportive, focusing on the management of heart failure symptoms and arrhythmias, with advanced cases necessitating heart transplantation. This review provides a comprehensive overview of EFE, highlighting the challenges in diagnosis and management and underscoring the need for further research to elucidate its pathogenesis and improve outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Ozdemir D, Cortopassi IO, McNamara RL. An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: a case report. Thromb J. 2019;17:8.
II. Chan JL, Rosing DR, Klion AD, Horvath KA. Surgical management of adult endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2017 Nov;154(5):e81-e84
III. Zhang H, Huang X, Liu K, Tang J, He L, Pu W, Liu Q, Li Y, Tian X, Wang Y, Zhang L, Yu Y, Wang H, Hu R, Wang F, Chen T, Wang QD, Qiao Z, Zhang L, Lui KO, Zhou B. Fibroblasts in an endocardial fibroelastosis disease model mainly originate from mesenchymal derivatives of epicardium. Cell Res. 2017 Sep;27(9):1157-1177.
IV. Weixler V, Hammer PE, Marx GR, Emani SM, Del Nido PJ, Friehs I. Flow disturbances and progression of endocardial fibroelastosis - a case report. Cardiovasc Pathol. 2019 Sep-Oct;42:1-3.
V. Ma F, Zhou K, Shi X, Wang X, Zhang Y, Li Y, Hua Y, Wang C. Misdiagnosed anomalous left coronary artery from the pulmonary artery as endocardial fibroelastosis in infancy: A case series. Medicine (Baltimore). 2017 Jun;96(24):e7199.
VI. .Hodgson S, Child A, Dyson M. Endocardial fibroelastosis: possible X linked inheritance. J Med Genet. 1987 Apr;24(4):210-4.
VII. Brady AN, Shehata BM, Fernhoff PM. X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene. Prenat Diagn. 2006 May;26(5):462-5.
VIII. .Aherrahrou Z, Schlossarek S, Stoelting S, Klinger M, Geertz B, Weinberger F, Kessler T, Aherrahrou R, Moreth K, Bekeredjian R, Hrabě de Angelis M, Just S, Rottbauer W, Eschenhagen T, Schunkert H, Carrier L, Erdmann J. Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis. Basic Res Cardiol. 2016 Jan;111(1):6.
IX. Weixler V, Marx GR, Hammer PE, Emani SM, Del Nido PJ, Friehs I. Flow disturbances and the development of endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2020 Feb;159(2):637-646.
X. Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ, Zeisberg EM. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res. 2015 Feb 27;116(5):857-66.
XI. Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010 Apr;20(2):115-23.
XII. Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JB, Silverman NH, Finley JP, Law YM, Human DG, Seaward PG, Hamilton RM, Hornberger LK. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation. 2002 Feb 19;105(7):843-8.
XIII. Raboisson MJ, Fouron JC, Sonesson SE, Nyman M, Proulx F, Gamache S. Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. J Am Soc Echocardiogr. 2005 Apr;18(4):375-80.
XIV. Harris LC, Nghiem QX. Cardiomyopathies in infants and children. Prog Cardiovasc Dis. 1972 Nov-Dec;15(3):255-87.